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Background: In January 2005, Rasulov et al. originally published “First experience in the use of bone marrow
mesenchymal stem cells (MSCs) for the treatment of a patient with deep skin burns”. Here, we present the first
ever treated patient with cadaveric bone marrow mesenchymal stem cells (CMSCs) in the history of Medicine.
Methods: A young man, who severely burned 60 % of his total body surface with 30 % of full-thickness burns while
working with a grass trimmer that exploded, was involved in the study. MSCs were obtained from the bone marrow of
a cadaver donor in a routine procurement procedure of CUCAIBA, the Province of Buenos Aires, Argentina, Ministry of
Health, Transplantation Agency, cultured, expanded, and applied on the burned surfaces using a fibrin spray after early
escharotomy.
Results: So far, our preliminary experience and our early results have been very impressive showing an outstanding
safety data as well as some impressive good results in the use of CMSCs.
Conclusions: Based on all this, we think that improvements in the use of stem cells for burns might be possible in the
near future and a lot of time as well as many lives could be saved by many other research teams all over the world.
CMSCs will probably be a real scientific opportunity in Regenerative Medicine as well as in Transplantation.
Keywords: Burns, Cadaveric, Transplantation, Skin regeneration, Mesenchymal stem cellsBackground
In January 2005, Rasulov et al. originally published “First
experience in the use of bone marrow mesenchymal stem
cells (MSCs) for the treatment of a patient with deep skin
burns”. This was the first treatment in the history of medi-
cine that used allogeneic MSCs in a human being with ex-
tensive skin burns [superficial to full-thickness skin burn,
total area 40 %, full-thickness burn area 30 %]. “Allogeneic
fibroblast-like bone marrow MSCs,” as designated at that
time by the authors, were placed onto the surface of a
deep and large thermal burn of a female patient. The* Correspondence: mansillaeduardo1@gmail.com
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(http://creativecommons.org/publicdomain/zedynamic of healing confirmed a high tempo of wound re-
generation in the presence of active neo-angiogenesis after
transplantation of these “fibroblast-like MSCs”. Due to
this, auto-dermoplasty of the burn wounds could be car-
ried out with good results as early as on day 4 after trans-
plantation of the stem cells, leading to a more rapid
healing of the donor zones and an accelerated rehabilita-
tion of the patient [1]. During that same month of January
2005, we published “Human mesenchymal stem cells are
tolerized by mice and improve skin and spinal cord injur-
ies,” in which we presented an accelerated healing process
of injured mice skins and spinal cords obtained by the use
of xenogeneic (human to mice) MSCs. In this way, im-
munological barriers were trespassed beyond species with-
out no rejection or adverse reactions to the transplanted
human stem cells or the mice, respectively, with very goode is distributed under the terms of the Creative Commons Attribution 4.0
.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
ive appropriate credit to the original author(s) and the source, provide a link to
changes were made. The Creative Commons Public Domain Dedication waiver
ro/1.0/) applies to the data made available in this article, unless otherwise stated.
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first time, “Bloodstream cells phenotypically identical to hu-
man mesenchymal bone marrow stem cells circulating in
large amounts under the influence of acute large skin dam-
age”. This was without any doubt, a new and paradigmatic
evidence for the future use of these cells in regenerative
medicine procedures, specially for the treatment of human
large burns. We also originally proposed in this paper that
it could be possible to mobilize MSCs from the bone mar-
row by induced therapeutic ways. These pharmacological
mechanisms could be very similar to those biochemical
alarm signals, naturally produced from damaged tissues, in
order to accomplish many regenerative mechanisms [3]. In
December 2010, we observed and published an “Outstand-
ing survival and regeneration process by the use of intelli-
gent acellular dermal matrices and MSCs”. This study was
done in a burned pig model in which an “intelligent” acellu-
lar biological pig dermis with nanoparticles and fibers
coated with an anti-CD44 monoclonal antibody and loaded
with growth factors like GM-CSF were implanted in a deep
severe wound bed after escharotomy of the burned tissue
[4]. In 2011, we presented to our Argentine regulatory au-
thority for organ, tissue and cell transplantation (INCU-
CAI) the first clinical trial protocol ever being designed in
the world using cadaveric bone marrow mesenchymal stem
cells (CMSCs) for the treatment of large burns. This was
communicated in an editorial to Burns: “Time and regener-
ation in burns treatment: heading into the first worldwide
clinical trial with cadaveric mesenchymal stem cells”, in
which we made special considerations about the import-
ance of time in the accomplishment of the regeneration
processes of wound healing, specially when stem cells are
used [5]. As this trial was approved (including the INCU-
CAI Ethic Committee review process and the signed con-
sent form), we treated the first patient by the end of that
year. CMSCs will probably be a real scientific opportunity
in Regenerative Medicine as well as in Transplantation [6].
We were the first research group in the world to use them
for regenerative purposes [5, 7]. There is still a great poten-
tial in these cells to be discovered. They might significantly
change in the near future the possible sources for stem cells
obtention. CMSCs could be very important tools to treat
burns as well as many other diseases [8–14]. By now, we
have made just a little advance in this new field of regenera-
tive medicine by using CMSCs for the treatment of large
and deep burns. Here, we present the first experience in the
world with this kind of cell treatment applied to a severe
burned patient after more than 3 years of follow-up.
Methods
Obtention and preparation of human CMSCs for
transplantation
Bone marrow blood was obtained by needle aspiration
from the iliac bone of a unique cadaver donor, in a routineprocurement procedure of our Province of Buenos Aires,
Argentina, Ministry of Health, Transplantation Agency,
CUCAIBA, after cardiac arrest and when all other organs
and tissues for transplantation were already collected. In
this procurement procedure, the donor was selected by his
negative tests for all adventitious agents, including hepa-
titis B and C, AIDS, syphilis, cytomegalovirus, and chagas,
among many others, as needed by law, for organ and tissue
transplantation. Briefly, 10 ml of heparinized bone marrow
blood was sterile and transported to our Tissue Engineer-
ing, Regenerative Medicine, and Cell Therapies Laboratory
in La Plata, Argentina, and processed in a clean room
under sterile and GMP conditions. Each 2 ml of this bone
marrow blood was diluted in 15 ml of low-glucose DMEM
(Gibco/Life Technologies) and cultured for the isolation of
MSC in 75 cm2 tissue culture flasks at 37 °C in a 5 % CO2
incubator at 95 % humidity with 10 % human platelet lys-
ate (HPL) obtained from platelet-rich plasma procured by
our Province of Buenos Aires Blood Bank. Few MSCs cells
were present in the initial inoculum, but after culture, they
expanded rapidly exponentially. MSCs appeared soon as
typical round colonies, and a monolayer started to form
over 14–17 days. When an 80 % of confluence was
obtained, MSCs were detached from the culture flasks,
expanded in a second passage, phenotyped as CD105-,
CD73-, CD44-, and CD90-positive cells, lacking CD45,
CD34, CD14, CD11b, CD79, CD19, and HLA-DR surface
molecules expression, microbiologically tested, karyotyped
as normal, and cryopreserved as needed. Cultured cells
were daily examined under a phase contrast inverted
microscope. The final samples before implantation were
always negative as tested for adventitious agents, and small
amounts of all of them were kept in quarantine for a
period of time after transplantation. There is not clearly a
certain or definitive amount of cells yet to be used in these
procedures, and the selected concentration for this trial
was based in previous work done by us in animal studies
and data presented by others before in different reports. A
final suspension of MSCs at a concentration of 1 × 106
cells/ml was prepared from the adherent cells in the plastic
flasks and mixed in a fraction of cryoprecipitate from
donor blood, with high amounts of fibrinogen and other
clotting factors, obtained from the same blood bank as the
HPL. A second component was also prepared with throm-
bin (Tissucol, Baxter) at a concentration of 5 U/ml of PBS.
Repairment of burn wound with CMSCs
A 26-year-old, young healthy male patient was admitted
to the Burns Unit at the San Martín Hospital, Province of
Buenos Aires Ministry of Health, in La Plata, Argentina,
on November 3, 2011, presenting with severe thermal
(flame) burns of both lateral and anterior parts of the ab-
domen, left and right armpits and tights, parts of the but-
tocks and the back, and total area up to 60 % body surface
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gency room that his clothes inflamed during fire while
using a grass trimmer that exploded. The burned surfaces
were washed, and supportive therapy was administered to
the patient. As the patient’s clinical condition improved,
combined treatment by traditional and new methods was
started, including early deep escharotomy of necrotic tis-
sue (Fig. 2), cell therapy with CMSCs, and posterior au-
tologous meshed skin grafting (AMSG) if needed.
Both solutions as mentioned in the “Obtention and prep-
aration of human cadaveric MSCs for transplantation” sec-
tion, one with the fibrinogen and MSCs and the other one
with thrombin, were introduced and preserved in two dif-
ferent sterile conical tubes at room temperature, trans-
ported within the next hour to the Burns Unit at the San
Martín Hospital of the Province of Buenos Aires, Ministry
of Health in La Plata, Argentina, and sprayed onto the
burn wound surface of the patient after deep escharotomy
at a density of 1 × 106 MSCs per 100 cm2, using a “duplo-Fig. 1 Deep burn on the right thigh. Necrotic burned tissue was
observed in the right thigh of the patient at admission to the hospitaljet” system. In this way, thrombin polymerized the fibrino-
gen of the cryoprecipitate fraction and adhered the cells
within a friendly fibrin matrix to the injured surface imme-
diately as it was sprayed over the wounded area. After cell
transplantation, the burned surfaces were dressed with a
sterile polymeric transparent film that was first changed on
day 7 and every other 2/3 days later on. A total of two
main courses of this kind of cell therapy were administered
to the wounded areas with 2-week difference between each
other. Wound healing process and efficacy of the cell ther-
apy was evaluated visually during wound observation on
days 1, 3, 6, 7, 9, 11, and 13 and then as needed. As we fo-
cused on the question of stem cell persistence and its de-
tection in the treated wound bed after its implantation, we
decided for practical methodology and ethical reasons not
to do so in this moment besides that it could have been a
great idea to finally elucidate MSC fate and possible differ-
entiation times and pathways when they have been trans-
planted in a human being from an allogeneic source as our
cadaver donor. Also, as there is no evidence of immuno-
logical rejection events by using allogeneic MSCs, we have
designed our procedure using CMSCs without the need of
HLA matching between the donor and recipient. Anyway,
we performed HLA typification of both the donor and the
patient’s cells. Also, we looked for microchimerism [14] as
well as any possible adverse effect related to immune in-
tolerance or rejection. It is very important to emphasize
that we were ready to document any possible adverse effect
at any time, with safety as being one of the main end points
of the trial. We have used as control group all patients with
similar type of skin lesions treated in our Burn Unit with
standard therapies in the past 10 years. Our efficacy end
points were mortality rate, days to complete healing of the
lesions, hospitalized total days, amount of surgery proce-
dures performed, functional sequelae, quality of the regen-
erated skin, and infectious complications, among many
others. As this is only one patient presented here, a statis-
tical analysis was not carried on yet to see the differences
in wound healing between CMSC-treated wounds and
non-CMSC-treated wounds.
Results
Surgical complete debridement of the necrotic burned tis-
sues were performed soon after admission of the patient
and cell therapy applied immediately (Fig. 2). Probably
due to some potential yet unknown properties of MSCs or
any of its transportation materials, or by the simultaneous
use of the polymeric transparent film as a dressing, lost of
plasma was not a concern, necrotic tissues were not ever
seen again after escharotomy at any site, and good blood
supply without wound infection was always present after
application of the stem cells (Fig. 3a). Bacteriological ana-
lysis of the wound surfaces and clinical observation did
not show evidence of local infection at any time. Burn
Fig. 2 Deep early escharotomy. a–d Escharotomy of severely burned tissue was performed during the first surgery
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the end of the first week after the cell treatment and every
third or fourth day later on, always covering the lesions
with the polymeric film. Antiseptics were not used at any
time. The transparent film dressing did not ever stick to
the wounded areas, and a yellowish fibrinoid material was
always present and seen under it (Fig. 3f). Besides this ob-
servation, other exudates were minimun under our film
not needing any special drainage. An increasing progres-
sive development of new capillaries were soon observed in
the surface of all treated wounds. A “granulation tissue-
like” appearance was evident in all the wounds by the fifth
day, and from this moment, “hyper-granulation” also devel-
oped and persisted on all treated burn wounds (Fig. 3a–f).
There was a fast and significant improvement of the clin-
ical condition of the patient, and pain in the burned areas
decreased in intensity. A surprisingly early and not very
well adherent thin epithelial growth was seen rapidly ad-
vancing from the wound edges in relation with the topical
cell therapy, but the “granulation-like” wound surface
remained almost unchanged in the center (Fig. 4a–b). After
35 days of treatment with two courses of CMSCs applica-
tion as described, the complete epithelialization of the
wounds seemed to be too slow to be waited further. Then,
after superficial surgical shaving of all the “hyper-granulat-
ing” areas, AMSG was applied. Skin grafts were obtained
from the non-burned zones, meshed and used to cover the
wound surfaces on every site. About 50 % of the remainingwound surface was covered during a first operation, and
additional transplantation of more auto-grafts were
done after another week always using the polymeric film
as a dressing. All AMSGs permanently adhered to the
wounded surfaces and were always viable. Interestingly,
the spaces inside the meshes seemed to rapidly and
completely epithelialized in a very short period of time.
The patient keeps continuously improving day after day,
leaving the bed and starting walking and moving with
significant freedom. He was finally discharged from the
hospital in a very well satisfactory condition for out-
patient rehabilitation and follow-up (Fig. 5a–f ). More
interesting is the fact that in the sites in which AMSGs
were applied, a slowly progressive integration of the
grafts with disappearance of their meshed aspect seems
to be taking place, looking more like normal skin. Al-
most no retraction is seen at any site, and the deep der-
mis as well as the epidermis seem to be normal again as
observed in CT scan studies (Fig. 6a–b).
Discussion
Similarity of results obtained in this study and by
Rasulov’s group
Our results seem to be very similar to those described
by the Rasulov’s group [1]. Both, Rasulov and us, have
seen an interesting fasting growth not only of a “granu-
lating dermal-like” tissue but also of a limited new epi-
dermis mainly from the wound edges. At the same time,
Fig. 3 Burn wounds were treated with cadaveric bone marrow mesenchymal stem cells (CMSCs) and covered by a transparent polymeric film. a The
patient at 1 week after deep escharotomy and first treatment with CMSCs and films. All the lesions have been washed and new film applied. Right axilla
was also seen before film application. b First film change at first week after the CMSC treatment. The granulation-like tissue was seen under
the film without much exudate. c–e One week after the first CMSC treatment, a granulation-like tissue was seen before first film replacement.
The granulation-like tissue was probably a very early vascularized “neo-dermal like matrix” after CMSCs treatment under an active growth and
differentiation natural program. This new matrix behaved as a novel and may be also “universal” scaffold allowing very well for autologous meshed skin
graftings (AMSGs) attachment and maybe later appearance of keratinocytes and the production of a mature epidermis. f Wound epithelialization at
second week after treatment with CMSCs. Rapid epithelialization from the edges and some epithelial growth in the center of the lesion was observed
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while using this type of therapy. There was a rapid devel-
opment of neo-angiogenesis in the lesions treated with
MSCs with a simultaneous growth of a granulation-like
tissue. Surprisingly, all these surfaces never showed anysign of infection or necrosis. Incipient epithelialization
was observed by us soon after the first week of CMSC im-
plantation, may be induced by the capacity of these allo-
geneic CMSCs to promote epithelial and endothelial
growth mainly as it was said before at the periphery of the
Fig. 4 Wound appearance without film at third week after first treatment with CMSCs. a Right axilla with granulation-like tissue was seen without film. b
“Incipient spontaneous” epithelialization in left flank. Hyper-proliferation of the granulation-like tissue was rapidly observed in all areas treated with CMSCs
Fig. 5 Burn wounds recovered at patient discharge. (a–f) At patient discharge, a slow integration of the grafts with progressive disappearance of their
meshed aspect seems to be taking place, looking more like normal skin. Good elasticity of the whole skin, almost no functional sequelae, limited hair
regrowth were observed in some areas in which MSCs have been applied
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Fig. 6 a–b CT scan studies. In CT scan studies, almost no skin retraction at any site is observed. Deep dermis as well as the epidermis seem to be
normal again
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fast epithelial growth was observed inside the meshed
spaces of the AMSGs. In further evaluations of the treated
deep wounds, limited hair regrowth was observed in some
areas. We have seen and described similar results in our
burned pig model [4]. Rasulov’s and our patient needed a
final epithelium replacement as it was described. We used
AMSGs while the other group applied “SGs” without
mentioning if they were meshed or not. The accelerated
growth of a new epithelium between the meshes that cov-
ered the entire empty spaces in a short period of time was
really amazing in our patient.
Differences observed between the study of Rasulov’s and
our’s
Differences between this study and Rasulov’s [1] were
observed by us: (1) the type of cells used by Rasulov
were designated as “allogeneic fibroblast FMSCs” but
their phenotype, features of the donor, testing for infec-
tious agents, or other data of these cells were not de-
scribed in their paper. Our’s were bone marrow MSCs
obtained from a unique cadaver donor and fulfilled the
phenotyping criteria for MSCs as well as all other re-
quirements by local law to be transplantable including
all the tests done to detect possible adventitious agents.No microchimerism was observed after several determina-
tions done at different moments of the patient’s follow-up
and no immune adverse events were seen at any time. (2)
The Russian group did not specify by which way they ap-
plied the cells on the surface of the patient’s wounds. We
sprayed the CMSCs into a blood cryoprecipitate that poly-
merized in situ. (3) Our cell culture method did not in-
volve the use of bovine fetal serum but HPL. It was
obtained from platelet-rich plasma having an outstanding
potential to promote the growth of CMSCs while main-
taining their phenotype and differentiation capacities. (4)
We have also always used a transparent polymeric film to
cover the wounds after the cell treatments. Rasulov’s
group employed just gauze. It is interesting to say that
every time stem cells with fibrin were used, a yellowish
creamy material under the film was always observed with
its characteristic appearance but without wound infection.
This could be a promoting interesting material for the
healing processes of the wounds that surely deserve fur-
ther studies and maybe also the essence for a future kind
of regenerative product. (5) The development of the
granulation-like tissue and its “hyper-proliferation” was
rapidly observed in all areas treated with CMSCs both by
us (as we also did in our previous pig burned model) and
Rasulov’s group.
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As far as we know, this is probably a very early vascular-
ized “neo-dermal-like matrix” under an active growth and
differentiation natural program, and not just simply a
“granulation tissue”. This new matrix behaves as a novel
and may be also as a “universal” scaffold allowing very well
for AMSG attachment and may be later appearance of
keratinocytes and the production of a mature epidermis.
In this way, keratinocytes could come at an early time
from the edges of the wounds or may be by direct differ-
entiation from resident MSCs later on after neo-matrix
organization [4].
The first experience using CMSCs in the treatment of a
burned patient
In any case, our future challenge in relation to the regen-
eration processes and in order to obtain a faster healing of
severe deep burns as well as many other lesions or dis-
eases of the body will surely be, as it was considered in
our previous editorial to Burns [5], a more precise man-
agement and understanding of the variable of time. In this
way, the needed length of time to completely regenerate a
full-thickness wound by the simple application of CMSCs
could be too long for this type of patients, even for the po-
tential growth and differentiation capacities of these cells.
In this scenario, we waited 35 days to apply the AMSGs,
while Rasulov’s group did it as soon as 4 days after the
cells were delivered on the wounds. Probably, it does not
really mean that MSCs do not have the potential to regen-
erate a complete skin including the epidermis, only that
maybe, more time could be needed as they have in this
kind of deep burns a long harder complicated work to do
by first rebuilding the vasculature and the matrix of a
neo-dermis before they could take care of the final re-
generation process for the development of a neo-
epidermis. By now, these preliminary results are very
promising by themselves. If time finally ends to be the
critical point, we might have several new major options
to be employed besides waiting for whole recovery by
the simple action of the cells: (1) To early apply the
AMSGs as soon as the granulation-like tissue induced
by MSCs is seen as Rasulov did. (2) To put together the
MSCs and the AMSGs or one specially made with “very
wide meshes”, expecting that the growth promotion ad-
vantages given by MSCs would be stimuli which is
enough to rapidly regenerate the whole skin in a
shorter period of time while needing and using much
less residual healthy skin from the patients for the
auto-grafting. (3) To early use cultured keratinocytes/
epidermal grafts or just keratinocyte stem cells with
MSCs. (4) To deliver MSCs in novel different ways like
in the shape of “spheroids” as we have previously de-
scribed [15]. This could accelerate the time to complete
regeneration specially if keratinocytes could also begrown in the outer surface of these spheroids. (5) To
potentially use “intelligent matrices” with nanoparticles
and stem cells to accelerate the time for healing [4]. It
is important to say that the patient did not have any ad-
verse effect at any time even after more than 3 years of
follow-up. He always showed a very well tolerance to the
treatment with CMSCs. At this moment, we see almost
no scar or deformity in the places treated with CMSCs.
The patient looks and feels clinically very good. There are
no functional sequelae, and he re-started to work very
soon after being discharged from the hospital.
Conclusions
This is mainly a descriptive as well as an observational
study of all the chronological events seen in this only
one and “first patient” treated in the world with CMSCs.
Our preliminary experience and our early results show
an outstanding safety data in the use of CMSCs in our
first severe burned patient treated in this way. Based on
all this, we think that improvements in the use of
CMSCs for burns might be possible in the near future,
and a lot of time as well as many lives could be saved by
many other research teams all over the world.
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